Skip to main content
SpringerLink
Log in

Myasthenia gravis linked with immune checkpoint inhibitors

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. CTLA-4 = cytotoxic T-lymphocyte-associated antigen-4; PD-1 = programmed cell death-protein-1

References

  1. Kim HJ, et al. Immune checkpoint inhibitor therapy: A double-edged sword? Neurology : [2 pages], 18 Aug 2017.

  2. Suzuki S, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology : [9 pages], 18 Aug 2017. Available from: URL: http://dx.doi.org/10.1212/WNL.0000000000004359.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Myasthenia gravis linked with immune checkpoint inhibitors. Reactions Weekly 1667, 8 (2017). https://doi.org/10.1007/s40278-017-35140-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-35140-4

Search

Navigation